loading
Intellia Therapeutics Inc stock is traded at $13.60, with a volume of 4.11M. It is up +6.38% in the last 24 hours and up +42.21% over the past month. Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.78
Open:
$12.82
24h Volume:
4.11M
Relative Volume:
0.90
Market Cap:
$1.41B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-2.4808
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+12.73%
1M Performance:
+42.21%
6M Performance:
+23.70%
1Y Performance:
-48.54%
1-Day Range:
Value
$12.73
$13.71
1-Week Range:
Value
$12.29
$14.40
52-Week Range:
Value
$5.90
$27.42

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
Name
Intellia Therapeutics Inc
Name
Phone
857-285-6200
Name
Address
40 ERIE STREET, CAMBRIDGE, MA
Name
Employee
598
Name
Twitter
@intelliatweets
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NTLA's Discussions on Twitter

Compare NTLA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
13.60 1.32B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-21-25 Upgrade Wolfe Research Peer Perform → Outperform
Mar-05-25 Initiated H.C. Wainwright Buy
Feb-28-25 Downgrade Goldman Neutral → Sell
Feb-28-25 Downgrade JP Morgan Overweight → Neutral
Jan-27-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-23-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Apr-13-23 Initiated Canaccord Genuity Buy
Mar-21-23 Initiated Bernstein Outperform
Mar-14-23 Upgrade BMO Capital Markets Market Perform → Outperform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Jan-24-23 Upgrade Citigroup Sell → Neutral
Jan-19-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-21-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Sell
Jun-17-22 Initiated BMO Capital Markets Market Perform
Jun-16-22 Initiated BofA Securities Buy
Apr-28-22 Initiated Credit Suisse Outperform
Feb-18-22 Initiated William Blair Outperform
Feb-07-22 Upgrade Oppenheimer Perform → Outperform
Jan-31-22 Initiated Cowen Outperform
Jan-07-22 Initiated Piper Sandler Overweight
Oct-05-21 Initiated Guggenheim Buy
Sep-24-21 Initiated Stifel Buy
Jun-28-21 Reiterated H.C. Wainwright Buy
Jun-11-21 Initiated H.C. Wainwright Buy
May-07-21 Upgrade ROTH Capital Neutral → Buy
May-04-21 Initiated RBC Capital Mkts Outperform
Mar-04-21 Initiated JMP Securities Mkt Outperform
Dec-22-20 Downgrade Robert W. Baird Outperform → Neutral
Oct-27-20 Initiated Truist Buy
Oct-14-20 Initiated Wells Fargo Overweight
Sep-18-20 Initiated Goldman Buy
Feb-28-20 Upgrade Oppenheimer Perform → Outperform
Feb-14-20 Downgrade Wedbush Outperform → Neutral
Nov-01-19 Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19 Initiated Robert W. Baird Outperform
Jun-10-19 Initiated ROTH Capital Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Evercore ISI Outperform
Nov-02-18 Downgrade Wedbush Outperform → Neutral
Oct-29-18 Initiated Credit Suisse Neutral
Sep-21-18 Initiated Raymond James Mkt Perform
May-15-18 Upgrade Chardan Capital Markets Neutral → Buy
Mar-08-18 Initiated JMP Securities Mkt Outperform
Nov-01-17 Reiterated Jefferies Buy
Jun-22-17 Resumed Jefferies Buy
Mar-28-17 Initiated Chardan Capital Markets Buy
Aug-05-16 Upgrade Jefferies Hold → Buy
View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

pulisher
Jul 25, 2025

NTLA CFO Sells 7,462 Shares in Tax Withholding Transaction – Form 4 | YGMZ SEC FilingForm 6-K - Stock Titan

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Intellia Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Intellia Therapeutics Inc. Stock Analysis and ForecastHigh-yield market plays - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

What makes Intellia Therapeutics Inc. stock attractive to long term investorsHigh-yield capital appreciation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Intellia Therapeutics Inc. a good long term investmentExtraordinary earning power - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Intellia Therapeutics Inc. stock priceFree Investment Community - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Will Intellia Therapeutics Inc. stock benefit from interest rate changesHigh-yield capital appreciation - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

How high can Intellia Therapeutics Inc. stock price go in 2025Accelerated financial growth - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks

Jul 24, 2025
pulisher
Jul 21, 2025

Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 18, 2025

Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 17, 2025

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Intellia Bets On CRISPR Breakthroughs Despite A Rocky Year - Finimize

Jul 16, 2025
pulisher
Jul 16, 2025

ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com

Jul 16, 2025
pulisher
Jul 09, 2025

Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st

Jul 09, 2025
pulisher
Jul 08, 2025

Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq

Jul 07, 2025
pulisher
Jul 03, 2025

Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus

Jul 03, 2025
pulisher
Jul 03, 2025

Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey

Jul 03, 2025
pulisher
Jul 02, 2025

Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus

Jul 02, 2025
pulisher
Jul 02, 2025

The Best Biotech Stocks to Buy - Morningstar

Jul 02, 2025
pulisher
Jun 28, 2025

Intellia Therapeutics gets FDA RMAT status for its heart disorder treatment - MSN

Jun 28, 2025
pulisher
Jun 25, 2025

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Zacks Investment Research

Jun 25, 2025
pulisher
Jun 23, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress - Insider Monkey

Jun 23, 2025
pulisher
Jun 22, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance

Jun 22, 2025
pulisher
Jun 21, 2025

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance

Jun 21, 2025
pulisher
Jun 18, 2025

Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News

Jun 18, 2025
pulisher
Jun 17, 2025

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025

Intellia Therapeutics Inc Stock (NTLA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):